1 Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390, 946-958, doi:10.1016/S0140-6736(17)30938-8 (2017).
2 Simões, E. A. F. et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther 7, 87-120, doi:10.1007/s40121-018-0188-z (2018).
3 Barr, R., Green, C. A., Sande, C. J. & Drysdale, S. B. Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis 6, 2049936119865798, doi:10.1177/2049936119865798 (2019).
4 Beigel, J. H. et al. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 167, 45-67, doi:10.1016/j.antiviral.2019.04.006 (2019).
5 Heylen, E., Neyts, J. & Jochmans, D. Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. Biochem Pharmacol 127, 1-12, doi:10.1016/j.bcp.2016.09.014 (2017).
6 McLellan, J. S., Ray, W. C. & Peeples, M. E. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372, 83-104, doi:10.1007/978-3-642-38919-1_4 (2013).
7 Anderson, C. S. et al. CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung. Pediatr Res 87, 862-867, doi:10.1038/s41390-019-0677-0 (2020).
8 Chirkova, T. et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 96, 2543-2556, doi:10.1099/vir.0.000218 (2015).
9 Johnson, S. M. et al. Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog 11, e1005318, doi:10.1371/journal.ppat.1005318 (2015).
10 Langedijk, J. P., Schaaper, W. M., Meloen, R. H. & van Oirschot, J. T. Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. J Gen Virol 77 ( Pt 6), 1249-1257, doi:10.1099/0022-1317-77-6-1249 (1996).
11 Griffiths, C. D. et al. IGF1R is an entry receptor for respiratory syncytial virus. Nature, doi:10.1038/s41586-020-2369-7 (2020).
12 Tayyari, F. et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17, 1132-1135, doi:10.1038/nm.2444 (2011).
13 Plotnicky-Gilquin, H. et al. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 73, 5637-5645 (1999).
14 Battles, M. B. & McLellan, J. S. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol 17, 233-245, doi:10.1038/s41579-019-0149-x (2019).
15 Tripp, R. A., Power, U. F., Openshaw, P. J. M. & Kauvar, L. M. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. J Virol 92, doi:10.1128/JVI.01302-17 (2018).
16 Arnold, R., König, B., Werchau, H. & König, W. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 330, 384-397, doi:10.1016/j.virol.2004.10.004 (2004).
17 Tripp, R. A. et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2, 732-738, doi:10.1038/90675 (2001).
18 Boyoglu-Barnum, S. et al. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective. J Virol 91, doi:10.1128/JVI.02059-16 (2017).
19 Caidi, H. et al. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Res 154, 149-157, doi:10.1016/j.antiviral.2018.04.014 (2018).
20 Cortjens, B. et al. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells. J Virol 91, doi:10.1128/JVI.02357-16 (2017).
21 Fedechkin, S. O., George, N. L., Wolff, J. T., Kauvar, L. M. & DuBois, R. M. Structures of respiratory syncytial virus G antigen bound to broadly neutralizing antibodies. Sci Immunol 3, doi:10.1126/sciimmunol.aar3534 (2018).
22 Ha, B. et al. Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. Vaccines (Basel) 7, doi:10.3390/vaccines7030069 (2019).
23 Jones, H. G. et al. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies. PLoS Pathog 14, e1006935, doi:10.1371/journal.ppat.1006935 (2018).
24 Lee, H. J., Lee, J. Y., Park, M. H., Kim, J. Y. & Chang, J. Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases. PLoS One 12, e0169139, doi:10.1371/journal.pone.0169139 (2017).
25 Nishi, A. et al. Deconstructing the traditional Japanese medicine "Kampo": compounds, metabolites and pharmacological profile of maoto, a remedy for flu-like symptoms. NPJ Syst Biol Appl 3, 32, doi:10.1038/s41540-017-0032-1 (2017).
26 Ohbuchi, K. et al. Differential annotation of converted metabolites (DAC-Met): Exploration of Maoto (Ma-huang-tang)-derived metabolites in plasma using high-resolution mass spectrometry. Metabolomics 16, 63, doi:10.1007/s11306-020-01681-3 (2020).
27 Nabeshima, S. et al. A comparison of oseltamivir with moat, a traditional herbal medicine, for the treatment of adult seasonal influenza A. J Trad Med 27, 148-156 (2010).
28 Nabeshima, S. et al. A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment of seasonal influenza. J Infect Chemother 18, 534-543, doi:10.1007/s10156-012-0378-7 (2012).
29 Masui, S. et al. Maoto, a Traditional Japanese Herbal Medicine, Inhibits Uncoating of Influenza Virus. Evid Based Complement Alternat Med 2017, 1062065, doi:10.1155/2017/1062065 (2017).
30 Shi, H. et al. Baicalin from Scutellaria baicalensis blocks respiratory syncytial virus (RSV) infection and reduces inflammatory cell infiltration and lung injury in mice. Sci Rep 6, 35851, doi:10.1038/srep35851 (2016).
31 Imai, T. et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521-530, doi:10.1016/s0092-8674(00)80438-9 (1997).
32 Feldman, S. A., Hendry, R. M. & Beeler, J. A. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 73, 6610-6617 (1999).
33 Hou, S., Xu, X., Wang, Y. & Yang, Y. Ephedrannin B exerts anti-viral and anti-inflammatory properties in BEAS-2B cells infected with respiratory syncytial virus. J Biosci 45 (2020).
34 Lee, J. W. et al. Grape Seed Proanthocyanidin Inhibits Mucin Synthesis and Viral Replication by Suppression of AP-1 and NF-κB via p38 MAPKs/JNK Signaling Pathways in Respiratory Syncytial Virus-Infected A549 Cells. J Agric Food Chem 65, 4472-4483, doi:10.1021/acs.jafc.7b00923 (2017).
35 Machado, V. B. et al. Biophysical and flavonoid-binding studies of the G protein ectodomain of group A human respiratory syncytial virus. Heliyon 5, e01394, doi:10.1016/j.heliyon.2019.e01394 (2019).
36 Tang, W. et al. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane. FASEB J 33, 4287-4299, doi:10.1096/fj.201800579R (2019).
37 Huang, T. P. et al. Characteristics of traditional Chinese medicine use in children with asthma: a nationwide population-based study. Allergy 68, 1610-1613, doi:10.1111/all.12273 (2013).
38 McKimm-Breschkin, J. L. A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining. J Virol Methods 120, 113-117, doi:10.1016/j.jviromet.2004.02.020 (2004).
39 Fuentes, S., Coyle, E. M., Golding, H. & Khurana, S. Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels. J Virol 89, 8193-8205, doi:10.1128/JVI.00133-15 (2015).